In patients with various disorders of haemostasis and in 13 controls we studied the capillary permeability to human 99Tc-albumin. In 16 haemophiliacs, in 2 afibrinogenaemics and in 1 out of 3 patients with von Willebrand’s disease with a factor VIII level of about 15% we observed a marked increase of capillary permeability. On the contrary, 2 patients with a congenital lack of factor V, 2 cases of von Willebrand’s disease with a factor VIII level of about 50% and 3 subjects with ITP showed a normal capillary permeability. The administration of a single small dose of factor VIII (1 U/kg) or IX (2 U/kg) or fibrinogen (15 mg/kg) which did not improve the clotting disorder corrected the permeability for at least 3 days. The induction of a severe clotting disorder by heparin administration in man and by anticoagulant treatment in rabbits did not change the capillary permeability. These results support the hypothesis that antihaemophilic factors and fibrinogen could be involved in the composition and functions of the vascular wall.

Keywords:
Afibrinogenaemia, Anticoagulants, Capillary permeability, Coagulation disorders, Factor VIII, Factor IX, Fibrinogen, Haemophilia
This content is only available via PDF.
© 1974 S. Karger AG, Basel
1974
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.